Key result
Lp(a) and ApoB/ApoA-I ratio provide complementary risk pathways in ACS, but lack prospective clinical validation.
Why the study?
Traditional lipid parameters are limited in accounting for residual cardiovascular risk, inherited lipid abnormalities, and overall atherosclerotic burden in ACS risk assessment.
Does the combined assessment of lipoprotein(a) and the ApoB/ApoA-I ratio improve risk stratification and prognostic evaluation compared to traditional lipid parameters in patients with acute coronary syndrome?
Does the combined assessment of lipoprotein(a) and the ApoB/ApoA-I ratio improve risk stratification and prognostic evaluation compared to traditional lipid parameters in patients with acute coronary syndrome?
Answers are grounded in this paper and cite their sources.
Integrating Lp(a) and the ApoB/ApoA-I ratio offers a dual-pathway framework capturing both plaque instability/thrombosis and atherogenic particle burden to address residual cardiovascular risk in ACS patients beyond LDL-C.
Acute coronary syndrome (ACS) is a critical clinical emergency resulting from the rupture or erosion of coronary atherosclerotic plaques and subsequent thrombosis. Its pathogenesis is driven by a complex interplay of dysregulated lipid metabolism, inflammatory responses, thrombotic processes, and genetic susceptibility. Although traditional lipid parameters are widely utilized in ACS risk assessment, they remain limited in their ability to account for residual cardiovascular risk, inherited lipid abnormalities, and the overall atherosclerotic burden. Lipoprotein(a) [Lp(a)], an independent, genetically determined cardiovascular risk factor, exhibits distinctive pro-atherogenic, pro-inflammatory, and pro-thrombotic properties. In parallel, the apolipoprotein B/apolipoprotein A-I (ApoB/ApoA-I) ratio reflects the equilibrium between atherogenic lipoprotein particles and anti-atherogenic lipoprotein functions, providing a more comprehensive measure of lipid-related metabolic risk. Recent evidence has highlighted the value of both biomarkers in assessing coronary lesion severity, plaque instability, and prognosis in ACS. This review synthesizes current findings regarding the pathophysiological basis, clinical utility, and potential for combined assessment of Lp(a) and the ApoB/ApoA-I ratio, while critically discussing the limitations of existing research. Future investigations should shift from univariate biomarker analysis toward multi-marker integration, risk reclassification, genetic stratification, and validation of targeted interventions to advance precision risk assessment and individualized management of ACS.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2026) conducted a review in Acute coronary syndrome (ACS). Combined assessment of lipoprotein(a) [Lp(a)] and the apolipoprotein B/apolipoprotein A-I (ApoB/ApoA-I) ratio vs. Traditional lipid parameters (such as LDL-C) or single-biomarker assessment was evaluated on Risk assessment, coronary lesion severity, plaque instability, and prognosis (major adverse cardiovascular events) in acute coronary syndrome. Lipoprotein(a) and the ApoB/ApoA-I ratio capture complementary prothrombotic and atherogenic pathways in acute coronary syndrome, though prospective validation of their combined predictive value is lacking.
Synapse has enriched 10 related papers. Consider them for comparative context: